From GlobeNewswire:

iTeos Therapeutics, Inc. will provide an update on their ongoing work at J.P. Morgan’s 42nd Annual Health Conference on January 10, 2024. The presentation will be held in San Francisco and broadcast live on the company’s investor webpage. After the event, the recording will be available for approximately 30 days.

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing new immuno-oncology treatments. Their innovative pipeline includes three clinical programs targeting validated immuno-oncology pathways, designed to improve clinical outcomes. The company is headquartered in Watertown, Massachusetts, and operates a research center in Gosselies, Belgium.

Investors can find important updates and information on iTeos Therapeutics’ investor webpage at www.iteostherapeutics.com. The company encourages current and potential investors to visit this page regularly for updates.

For further information, please contact:

Investor Relations:
Carl Mauch
iTeos Therapeutics, Inc.
[email protected]

Media Contact:
[email protected]



Read more: iTeos présentera ses travaux lors de la 42e conférence